Mallinckrodt’s most critical drug, Acthar Gel, has a long history of price hikes that could prove a liability for shareholders as watchdogs continue adding new pressure across the industry.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
